Overview

Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

Status:
Completed
Trial end date:
2021-05-04
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-864 in PiZZ subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated